Max  Reinhardt net worth and biography

Max Reinhardt Biography and Net Worth

Insider of Pacira BioSciences
Max Reinhardt joined Pacira in June 2019 and serves as President, Rest of World. In this capacity Mr. Reinhardt oversees global commercialization efforts for the Pacira portfolio, as well as the company’s payer and employer relations activities and key customer partnerships. Mr. Reinhardt has twenty-five years of medical device experience and has held positions of increasing responsibility in sales, marketing and general management. Most recently he served as Vice President, Marketing at DePuy Synthes, where he led the negotiations and launch of the Pacira alliance to bring EXPAREL® to orthopedic customers nationwide. Prior to this role, Mr. Reinhardt served in several capacities at Johnson & Johnson including Director of Sales and Marketing for DePuy Spine in 2002, where he led the UK spine business before relocating to the US as Vice President of US Sales for DePuy Spine in 2006. In 2011 he was named Vice President, Worldwide Marketing, a position in which he played a key role in the acquisition and integration of Synthes Spine. In 2012 he was named Worldwide President, DePuy Synthes Spine, and led the spine business through the first two years of integration. Mr. Reinhardt was also responsible for the DePuy Synthes Joint Reconstruction, Mitek Sports Medicine, Early Intervention and the Power Tools divisions between 2015 and 2016. Prior to his time at Johnson & Johnson, Mr. Reinhardt served in sales leadership roles at both Olympus KeyMed and STERIS Corporation in the UK.

Mr. Reinhardt earned his Higher National Diploma at Sparsholt College of Agriculture in the UK and his Master of Science degree in marketing from the University of Hull, England.

What is Max Reinhardt's net worth?

The estimated net worth of Max Reinhardt is at least $800,139.00 as of October 7th, 2022. Mr. Reinhardt owns 31,378 shares of Pacira BioSciences stock worth more than $800,139 as of April 25th. This net worth estimate does not reflect any other assets that Mr. Reinhardt may own. Learn More about Max Reinhardt's net worth.

How do I contact Max Reinhardt?

The corporate mailing address for Mr. Reinhardt and other Pacira BioSciences executives is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. Pacira BioSciences can also be reached via phone at (813) 553-6680 and via email at [email protected]. Learn More on Max Reinhardt's contact information.

Has Max Reinhardt been buying or selling shares of Pacira BioSciences?

Max Reinhardt has not been actively trading shares of Pacira BioSciences during the last quarter. Most recently, Max Reinhardt sold 1,380 shares of the business's stock in a transaction on Friday, October 7th. The shares were sold at an average price of $58.00, for a transaction totalling $80,040.00. Following the completion of the sale, the insider now directly owns 31,378 shares of the company's stock, valued at $1,819,924. Learn More on Max Reinhardt's trading history.

Who are Pacira BioSciences' active insiders?

Pacira BioSciences' insider roster includes Donald Manning (Insider), Max Reinhardt (Insider), Charles Reinhart, III (CFO), Lauren Riker (VP), David Stack (CEO), Andreas Wicki (Director), Kristen Williams (Insider), and Roy Winston (Insider). Learn More on Pacira BioSciences' active insiders.

Are insiders buying or selling shares of Pacira BioSciences?

In the last twelve months, insiders at the sold shares 16 times. They sold a total of 138,857 shares worth more than $4,613,719.15. The most recent insider tranaction occured on March, 8th when Director Gary W Pace sold 90,000 shares worth more than $2,754,000.00. Insiders at Pacira BioSciences own 6.6% of the company. Learn More about insider trades at Pacira BioSciences.

Information on this page was last updated on 3/8/2024.

Max Reinhardt Insider Trading History at Pacira BioSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/7/2022Sell1,380$58.00$80,040.0031,378View SEC Filing Icon  
4/21/2022Sell9,824$73.25$719,608.0029,650View SEC Filing Icon  
4/19/2022Sell9,321$72.25$673,442.2524,238View SEC Filing Icon  
7/2/2021Sell421$59.76$25,158.96View SEC Filing Icon  
6/7/2021Sell2,278$60.50$137,819.0012,778View SEC Filing Icon  
1/6/2021Sell110$60.81$6,689.10View SEC Filing Icon  
11/13/2020Sell25,000$63.38$1,584,500.0039,000View SEC Filing Icon  
9/17/2020Sell25,420$59.81$1,520,370.2039,000View SEC Filing Icon  
See Full Table

Max Reinhardt Buying and Selling Activity at Pacira BioSciences

This chart shows Max Reinhardt's buying and selling at Pacira BioSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pacira BioSciences Company Overview

Pacira BioSciences logo
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Read More

Today's Range

Now: $25.50
Low: $25.33
High: $26.00

50 Day Range

MA: $28.76
Low: $25.50
High: $31.41

2 Week Range

Now: $25.50
Low: $25.33
High: $48.60

Volume

305,832 shs

Average Volume

424,158 shs

Market Capitalization

$1.19 billion

P/E Ratio

31.48

Dividend Yield

N/A

Beta

0.76